These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 25541715)
21. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Rounbehler RJ; Berglund AE; Gerke T; Takhar MM; Awasthi S; Li W; Davicioni E; Erho NG; Ross AE; Schaeffer EM; Klein EA; Karnes RJ; Jenkins RB; Cleveland JL; Park JY; Yamoah K Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1376-1383. PubMed ID: 30108099 [No Abstract] [Full Text] [Related]
22. Low tristetraprolin expression promotes cell proliferation and predicts poor patients outcome in pancreatic cancer. Wei ZR; Liang C; Feng D; Cheng YJ; Wang WM; Yang DJ; Wang YX; Cai QP Oncotarget; 2016 Apr; 7(14):17737-50. PubMed ID: 26894969 [TBL] [Abstract][Full Text] [Related]
23. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Rounbehler RJ; Fallahi M; Yang C; Steeves MA; Li W; Doherty JR; Schaub FX; Sanduja S; Dixon DA; Blackshear PJ; Cleveland JL Cell; 2012 Aug; 150(3):563-74. PubMed ID: 22863009 [TBL] [Abstract][Full Text] [Related]
24. Tristetraprolin exerts tumor suppressive functions on the tumorigenesis of glioma by targeting IL-13. Zeng B; Zhu D; Su Z; Li Z; Yu Z Int Immunopharmacol; 2016 Oct; 39():63-70. PubMed ID: 27424080 [TBL] [Abstract][Full Text] [Related]
25. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718 [TBL] [Abstract][Full Text] [Related]
26. Dysregulation of TTP and HuR plays an important role in cancers. Wang H; Ding N; Guo J; Xia J; Ruan Y Tumour Biol; 2016 Nov; 37(11):14451-14461. PubMed ID: 27644249 [TBL] [Abstract][Full Text] [Related]
27. Insulin increases tristetraprolin and decreases VEGF gene expression in mouse 3T3-L1 adipocytes. Cao H; Urban JF; Anderson RA Obesity (Silver Spring); 2008 Jun; 16(6):1208-18. PubMed ID: 18388887 [TBL] [Abstract][Full Text] [Related]
28. Tristetraprolin suppresses AHRR expression through mRNA destabilization. Lee HH; Kim WT; Kim DH; Park JW; Kang TH; Chung JW; Leem SH FEBS Lett; 2013 May; 587(10):1518-23. PubMed ID: 23583445 [TBL] [Abstract][Full Text] [Related]
29. Bi-phased regulation of the post-transcriptional inflammatory response by Tristetraprolin levels. Mahmoud L; Moghrabi W; Khabar KSA; Hitti EG RNA Biol; 2019 Mar; 16(3):309-319. PubMed ID: 30664390 [TBL] [Abstract][Full Text] [Related]
30. FOXO1 Is a Key Mediator of Glucocorticoid-Induced Expression of Tristetraprolin in MDA-MB-231 Breast Cancer Cells. Jeon DY; Jeong SY; Lee JW; Kim J; Kim JH; Chu HS; Jeong WJ; Lee BJ; Ahn B; Kim J; Choi SH; Park JW Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430156 [TBL] [Abstract][Full Text] [Related]
31. Establishment of a CALU, AURKA, and MCM2 gene panel for discrimination of metastasis from primary colon and lung cancers. Nasri Nasrabadi P; Nayeri Z; Gharib E; Salmanipour R; Masoomi F; Mahjoubi F; Zomorodipour A PLoS One; 2020; 15(5):e0233717. PubMed ID: 32469983 [TBL] [Abstract][Full Text] [Related]
32. The Tristetraprolin Family of RNA-Binding Proteins in Cancer: Progress and Future Prospects. Saini Y; Chen J; Patial S Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545247 [TBL] [Abstract][Full Text] [Related]
33. The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin. Wu X; Tommasi di Vignano A; Zhou Q; Michel-Dziunycz PJ; Bai F; Mi J; Qin J; Zu T; Hofbauer GFL PLoS Genet; 2018 May; 14(5):e1007366. PubMed ID: 29723192 [TBL] [Abstract][Full Text] [Related]
34. Dysregulation of tristetraprolin and human antigen R promotes gastric cancer progressions partly by upregulation of the high-mobility group box 1. Wang H; Chen Y; Guo J; Shan T; Deng K; Chen J; Cai L; Zhou H; Zhao Q; Jin S; Xia J Sci Rep; 2018 May; 8(1):7080. PubMed ID: 29728635 [TBL] [Abstract][Full Text] [Related]
35. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276 [TBL] [Abstract][Full Text] [Related]
36. Effects of Combined Tristetraprolin/Tumor Necrosis Factor Receptor Deficiency on the Splenic Transcriptome. Patial S; Stumpo DJ; Young WS; Ward JM; Flake GP; Blackshear PJ Mol Cell Biol; 2016 May; 36(9):1395-411. PubMed ID: 26976640 [TBL] [Abstract][Full Text] [Related]
37. Regulation of tristetraprolin expression by interleukin-1 beta and dexamethasone in human pulmonary epithelial cells: roles for nuclear factor-kappa B and p38 mitogen-activated protein kinase. King EM; Kaur M; Gong W; Rider CF; Holden NS; Newton R J Pharmacol Exp Ther; 2009 Aug; 330(2):575-85. PubMed ID: 19435930 [TBL] [Abstract][Full Text] [Related]
38. Wnt/CTNNB1 Signal Transduction Pathway Inhibits the Expression of ZFP36 in Squamous Cell Carcinoma, by Inducing Transcriptional Repressors SNAI1, SLUG and TWIST. Zanfi ED; Fantini S; Lotti R; Bertesi M; Marconi A; Grande A; Manfredini R; Pincelli C; Zanocco-Marani T Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784485 [TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival. Upadhyay R; Sanduja S; Kaza V; Dixon DA Int J Cancer; 2013 Feb; 132(3):E128-38. PubMed ID: 22907529 [TBL] [Abstract][Full Text] [Related]
40. linc-SCRG1 accelerates liver fibrosis by decreasing RNA-binding protein tristetraprolin. Wu JC; Luo SZ; Liu T; Lu LG; Xu MY FASEB J; 2019 Feb; 33(2):2105-2115. PubMed ID: 30226813 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]